Clinical Trials Logo

Anxiety, Separation clinical trials

View clinical trials related to Anxiety, Separation.

Filter by:

NCT ID: NCT00255112 Completed - Clinical trials for Separation Anxiety Disorder

TAFF-Psychological Treatment of Separation Anxiety Disorder

Start date: June 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a specific family based cognitive behavioral treatment program is effective in the treatment of children with separation anxiety disorder.

NCT ID: NCT00104195 Completed - Anxiety Disorders Clinical Trials

A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions

Start date: February 2004
Phase: Phase 1
Study type: Observational

The purpose of this trial is to study how teens with and without an anxiety disorder make decisions. This is a brain imaging study using functional magnetic resonance imaging (fMRI) in adolescents between the ages of 13 and 17.

NCT ID: NCT00012584 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Treatment of Youth With ADHD and Anxiety

Start date: November 2000
Phase: N/A
Study type: Interventional

The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.

NCT ID: NCT00000389 Completed - Anxiety Disorders Clinical Trials

Treatment for Anxiety in Children

Start date: October 1996
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see if it is effective to treat children with anxiety disorders with fluvoxamine. Fluvoxamine has been successfully used to treat obsessive-compulsive disorder (OCD) in adults and children. Anxiety disorders other than OCD, such as generalized anxiety disorder, social phobia, or separation anxiety, are very common in youth and are not always responsive to behavioral therapies alone. These disorders may respond to fluvoxamine. A child will be evaluated for 3 weeks before he/she is assigned randomly (like tossing a coin) to receive either fluvoxamine or an inactive placebo for 8 weeks. After this double-blind phase (neither the child/parents nor the doctor know which treatment is being given), the child will have the option of continuing treatment during a 4-month open-label extension period (both the child/parents and the doctor know which the child is receiving). A child may be eligible for this study if he/she: Is 6 to 17 years old and has been diagnosed with an anxiety disorder (i.e., generalized anxiety disorder, social phobia, or separation anxiety).